Today, the CEO & President of VBI Vaccines (VBIV), Jeff Baxter, bought shares of VBIV for $75K.
This recent transaction increases Jeff Baxter’s holding in the company by 32.73% to a total of $300.5K. In addition to Jeff Baxter, one other VBIV executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on VBI Vaccines’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $640K and GAAP net loss of $13.17 million. In comparison, last year the company earned revenue of $259K and had a GAAP net loss of $15.37 million. The company has a one-year high of $2.78 and a one-year low of $0.47.
Starting in November 2018, VBIV received 17 Buy ratings in a row.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VBI Vaccines, Inc. is a biopharmaceutical company. It engages in the development of eVLP vaccine platform for the design of (e) virus-like-particle vaccines that closely mimic the target virus.
